Lab Manager | Run Your Lab Like a Business

Single-Cell Proteomic Pathway Omics

Identifying adaptive signaling pathways for designing improved targeted therapies

Single-Cell Proteomic Pathway Omics

IsoPlexis’ Single-Cell Intracellular Proteome uniquely measures phosphorylation events that define signaling cascades and adaptive resistance pathways, uncovering the mechanisms of functional adaptations, disease progression, and therapeutic resistance

IsoPlexis

Q: How do you detect the changes in signaling pathways involved in drug resistance?

One of the biggest challenges in treating cancers is their ability to rapidly develop drug-tolerance. Uncovering the mechanisms behind this cell-state change is vital but difficult to obtain with traditional methods. Researchers often look to genomic markers to understand the tumor microenvironment and signaling pathways; however, functional adaptations can occur in the tumor that are unrecorded in their genomic signatures. Traditional flow-based methods detect a single cancer signaling pathway once it has been activated, so, once resistance develops and the tumor returns, additional experimental runs must be developed and performed to overcome this resistance. Using genomics alone has also led to challenges for researchers as providing a complete picture of a tumor’s mechanisms of therapeutic resistance is quite difficult and drugs targeted to those pathways have still resulted in drug tolerance.

A:With our single-cell proteomic pathway omics, you can elucidate networked pathways and better understand drug mechanisms.  

IsoPlexis’ single-cell phosphoproteomics is the only method available that can provide a comprehensive picture of highly multiplexed tumor signaling pathways and phosphorylation events that define signaling cascades directly from each cell. IsoPlexis’ single-cell pathway omics provides the missing data layer that enables the development of effective combination therapies by identifying the mechanisms of drug resistance before it occurs. Targeting functional adaptations prior to activation has been an effective strategy for the prevention of resistance, and with IsoPlexis’ platform multiple resistance pathways can be detected to determine the most effective target. By highly multiplexing 15+ signaling proteins across thousands of single cells in parallel, this solution enables predictive intracellular discoveries, revealing true functional biology to accelerate research and medicine.

To learn more, visit: isoplexis.com/scicp-ebook